Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Minesh Patel (NPI 1699094300)

Field	Value
Entity Type	Individual
Organization	Minesh Patel
Address	775 Poplar Rd Ste 310
City	Newnan
State	GA
ZIP	30265
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 19, 2010

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This is a Hematology & Oncology physician whose billing mix is dominated by high-cost oncology infusions and associated supportive care agents; the top drugs billed are pembrolizumab (J9271), cemiplimab (J9119), and denosumab (J0897), and the presence of filgrastim/pegfilgrastim and IV iron codes indicates an infusion-centered oncology clinic delivering both cancer-directed biologics and supportive therapies. The combination of oncology drug J-codes and chemotherapy administration CPTs suggests on-site infusion services rather than a pure office-based consult practice.

Revenue is heavily concentrated in a very small set of Medicare drug codes: the precomputed top 3 Medicare codes account for 74.2% of this provider's total Medicare revenue, with J9271 alone representing $1M (43.1% of Medicare revenue) and J9119 and J0897 contributing $495.6K (21.0%) and $238.7K (10.1%) respectively; these three codes are the primary drivers of the reported $2.4M in lifetime Medicare revenue. This degree of concentration implies that fluctuations in utilization or reimbursement for those agents would materially affect the provider’s Medicare revenue.

Payer mix is effectively single-payer: the provider reports $2.4M in total Medicare revenue and has no Medicaid billing on file, so Medicare is the dominant and effectively sole public payer represented in the claims dataset. Analysts should treat Medicaid-driven conclusions as inapplicable here given the absence of Medicaid activity.

Competitive standing on the headline oncology agents is mixed: J9271 ranks #229 of 1841 nationally (87th percentile; typical, unremarkable volume), indicating solid but not dominant national volume for pembrolizumab; J9119 ranks #4 of 5 providers nationally (25th percentile; typical, unremarkable volume), a ranking that reflects a very small reporting pool and should be interpreted cautiously; J0897 ranks #687 of 10057 (93th percentile; typical, unremarkable volume), placing denosumab use well above many peers. Together these ranks show the provider is a meaningful regional participant for some agents and occupies higher-than-average standing for certain supportive oncology drugs.

Several CPT codes are statistical outliers relative to national peers: 99213 is listed at the 98th percentile and labeled an extreme outlier, and 96372 is at the 99th percentile and also labeled an extreme outlier, which together show unusually high volumes of routine E/M visits and standalone injections compared to national norms. High E/M and injection volumes are consistent with frequent follow-up visits and frequent supervised administration of injectable therapies in an oncology infusion setting.

Chemotherapy administration activity is elevated versus peers: 96413 appears at the 95th percentile and is labeled notably above typical national volume, 96402 is at the 96th percentile (notably above typical), and 96417 is at the 90th percentile (typical, unremarkable volume). These add-on and primary chemotherapy administration codes corroborate that the provider delivers active IV/subcutaneous chemotherapy regimens on-site rather than merely prescribing them.

Use of growth factors and supportive hematology products is comparatively high: J1442 (filgrastim) is ranked #2 of 39 providers nationally (97th percentile; typical, unremarkable volume) and J2506 (pegfilgrastim) sits at the 89th percentile, indicating above-average use of granulocyte colony-stimulating factors consistent with active cytotoxic chemotherapy caseloads. The presence of darbepoetin (J0881) and multiple IV iron codes (J1437, J1439) further supports a broad supportive-care offering for anemia and neutropenia management.

The provider’s NPI was enumerated on 2010-05-19 (~16 years ago), indicating an established billing history; combined with the concentrated oncology drug revenue and persistent high-volume administration/E&M codes, this tenure suggests a stable, ongoing infusion practice with an entrenched referral and treatment workflow rather than a recent or transient billing pattern.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	24,800	$40	$1M
J9119	Injection, cemiplimab-rwlc, 1 mg	24,780	$20	$495.6K
J0897	Injection, denosumab, 1 mg	13,260	$20	$238.7K
J1437	Injection, ferric derisomaltose, 10 mg	5,300	$20	$84.8K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	3,060	$20	$64.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	840	$70	$61.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	29,000	$1	$58K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$90	$56.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	880	$60	$52.9K
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	45,240	$1	$45.2K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Minesh Patel — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	40	15,200	$40	$767.3K
J9119	1	10	24,780	$20	$500.2K
J0897	24	290	2,460	$20	$90.2K
Q5107	4	10	3,280	$20	$69.8K
J1437	6	30	2,850	$20	$56.4K
J3315	6	10	140	$290	$56.2K
J0881	2	20	15,200	$1	$37.1K
J2506	1	10	460	$80	$34.1K
J1439	25	30	28,130	$1	$32.3K
J1454	11	20	80	$330	$25.9K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Minesh Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Cogent Healthcare Of Georgia PC	GA	Internal Medicine Physician	$0	$4.6M
Vasileios Assikis	GA	Hematology & Oncology Physician	$3M	$0
Jonathan Bender	GA	Hematology & Oncology Physician	$2.6M	$0
Vipin Ramprasad Lohiya	GA	Hematology & Oncology Physician	$2.3M	$0
William Jonas	GA	Hematology & Oncology Physician	$1.8M	$0
Trevor Feinstein	GA	Hematology & Oncology Physician	$1.4M	$0
Jay Rhee	GA	Hematology & Oncology Physician	$871.7K	$0
Nikita Amin	GA	Hematology & Oncology Physician	$444.2K	$0
Hakeem Ayinde	VA	Clinical Cardiac Electrophysiology Physician	$426.4K	$0
Marc Coan	GA	Internal Medicine Physician	$261.3K	$0

Nearby Providers

Other providers in the same ZIP code as Minesh Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wellstreet Of Georgia PC	GA	Urgent Care Clinic/Center	$0	$42.5M
Adonness Bell	GA	Family Nurse Practitioner	$53.9K	$5.6M
My Kidz Dentist, PC	GA	Pediatric Dentistry	$0	$3.9M
Oghenerukevwe Odiete	GA	Interventional Cardiology Physician	$1.2M	$0
Southern Bone & Joint Ambulatory Surgical Center, LLC	GA	Ambulatory Surgical Clinic/Center	$1.2M	$0
Center For Pain And Spine, LLC	GA	Ambulatory Surgical Clinic/Center	$827.2K	$0
Derek Scott	GA	Physical Medicine & Rehabilitation Physician	$593.9K	$0
James Smith	GA	Physician Assistant	$576.9K	$0
Ayesha Faruqi	GA	Internal Medicine Physician	$262.5K	$0
David Harvey	GA	MOHS-Micrographic Surgery Physician	$258.4K	$0

Minesh Patel — Billing Profile & Reimbursement Data

Sign up for Minesh Patel — Billing Profile & Reimbursement Data policy alerts

Minesh Patel — Billing Profile & Reimbursement Data

Sign up for Minesh Patel — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References